argenx (ARGX) Projected to Post Earnings on Thursday

argenx (NASDAQ:ARGX) is expected to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect argenx to post earnings of $0.98 per share and revenue of $748.34 million for the quarter.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $761.22 million for the quarter, compared to analysts’ expectations of $678.52 million. On average, analysts expect argenx to post $3 EPS for the current fiscal year and $11 EPS for the next fiscal year.

argenx Stock Performance

Shares of NASDAQ:ARGX opened at $656.65 on Tuesday. The firm has a market capitalization of $40.10 billion, a P/E ratio of -746.19 and a beta of 0.57. The stock has a 50 day moving average price of $598.99 and a 200-day moving average price of $612.98. argenx has a 52-week low of $352.77 and a 52-week high of $678.21.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Truist Financial reissued a “buy” rating and set a $700.00 price objective (up previously from $660.00) on shares of argenx in a research report on Tuesday, January 14th. William Blair restated an “outperform” rating on shares of argenx in a report on Friday, February 28th. Sanford C. Bernstein upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a report on Monday, March 17th. Piper Sandler raised their price objective on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research report on Tuesday, January 7th. Finally, Citigroup boosted their target price on argenx from $681.00 to $796.00 and gave the stock a “buy” rating in a report on Thursday, April 17th. Three investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, argenx presently has a consensus rating of “Moderate Buy” and a consensus target price of $699.28.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.